Human Multi-Organoid Platform to Model Immune Dynamics in Cardiac Injury and Disease.

Circ Res

MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Birmingham, United Kingdom. (Y.S., A.O.K.).

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCRESAHA.125.326823DOI Listing

Publication Analysis

Top Keywords

human multi-organoid
4
multi-organoid platform
4
platform model
4
model immune
4
immune dynamics
4
dynamics cardiac
4
cardiac injury
4
injury disease
4
human
1
platform
1

Similar Publications

Human organoids to assess environmental contaminants toxicity and mode of action: towards New Approach Methodologies.

J Hazard Mater

August 2025

Department of Biomedical Sciences, University of Lausanne, Rue du Bugnon 7, Lausanne 1005, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland. Electronic address:

The global rise of environmental contaminants (ECs), including microplastics, heavy metals, pesticides, and drugs, poses an urgent threat to human health. Traditional toxicological models often fail to replicate human-specific responses, delaying effective risk assessment and regulation. Conversely, human organoid models represent a breakthrough in environmental health research by offering unprecedented physiological relevance.

View Article and Find Full Text PDF

Despite significant advances in cancer immunotherapy, current approaches face critical limitations, including systemic toxicity, inadequate tumor penetration, and insufficient therapeutic efficacy against immunosuppressive tumor microenvironments. A significant research gap exists in developing platforms that can simultaneously address these challenges while providing real-time monitoring capabilities. We critically analyze recent innovations in scaffold-based delivery systems that enable the controlled release of immunomodulatory agents directly within tumor microenvironments, thereby minimizing systemic exposure and associated toxicities.

View Article and Find Full Text PDF

Advances in human cellular mechanistic understanding and drug discovery of brain organoids for neurodegenerative diseases.

Ageing Res Rev

December 2024

Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China; Hunan Provincial Key Laboratory of Complex Effects Analysis for Chinese Patent Medic

Article Synopsis
  • * Traditional 2D cultures and animal models are not suitable for developing therapies, but 3D human brain organoids (hBOs) provide a more accurate way to study these diseases and test potential drugs.
  • * This study highlights the use of hBOs in understanding neurodegenerative diseases like Alzheimer's and Parkinson's by creating brain region-specific organoids that mimic real brain structures and functions, encouraging further research on their development.
View Article and Find Full Text PDF

Mature primary human osteocytes in mini organotypic cultures secrete FGF23 and PTH1-34-regulated sclerostin.

Front Endocrinol (Lausanne)

May 2023

Botnar Institute for Musculoskeletal Sciences, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

Introduction: For decades, functional primary human osteocyte cultures have been crucially needed for understanding their role in bone anabolic processes and in endocrine phosphate regulation via the bone-kidney axis. Mature osteocyte proteins (sclerostin, DMP1, Phex and FGF23) play a key role in various systemic diseases and are targeted by successful bone anabolic drugs (anti-sclerostin antibody and teriparatide (PTH1-34)). However, cell lines available to study osteocytes produce very little sclerostin and low levels of mature osteocyte markers.

View Article and Find Full Text PDF